Parkinson Disease

An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial

Authors: Niraj M Shanbhag, Jaya L Padmanabhan, Zheng Zhang, Brian T Harel, Hongxia Jia, Tairmae Kangarloo, Wei Yin, Ariel V Dowling, Antonio Laurenza, Polyna Khudyakov, Kevin Galinsky, Robert D Latzman, Tanya Simuni, Daniel Weintraub, Fay B Horak, Cindy Lustig, Paul Maruff, Arthur A Simen

Journal: JAMA Neurology

Year Published: 2025

Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment. Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants […]

Back to Publications

Cogstate
© 2025 Cogstate Ltd.

Cogstate acknowledges Aboriginal and Torres Strait Islander people as the Traditional Custodians of the lands where many of our team members live and work. We pay respect to their Elders past and present.